- Home
- CIA vs GLSI Comparison
CIA vs GLSI Comparison
Compare CIA & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CIA | GLSI |
|---|---|---|
| Founded | 1969 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Life Insurance | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 300.3M | 244.7M |
| IPO Year | 1995 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CIA | GLSI |
|---|---|---|
| Price | $3.51 | $19.63 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $50.00 |
| AVG Volume (30 Days) | 105.9K | ★ 112.6K |
| Earning Date | 05-07-2026 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $255,616,000.00 | N/A |
| Revenue This Year | $3.10 | N/A |
| Revenue Next Year | $4.47 | N/A |
| P/E Ratio | $28.23 | ★ N/A |
| Revenue Growth | ★ 4.33 | N/A |
| 52 Week Low | $3.39 | $7.78 |
| 52 Week High | $6.54 | $34.10 |
Technical Indicators
Market Signals| Indicator | CIA | GLSI |
|---|---|---|
| Relative Strength Index (RSI) | 31.45 | 64.93 |
| Support Level | N/A | $17.96 |
| Resistance Level | $4.04 | $19.64 |
| Average True Range (ATR) | 0.18 | 1.08 |
| MACD | 0.01 | 0.34 |
| Stochastic Oscillator | 13.53 | 92.28 |
Price Performance
Historical ComparisonAbout CIA Citizens Inc. ($1.00 Par)
Citizens Inc is an insurance holding company serving the life insurance needs of individuals in the United States. The company provides insurance benefits to residents in thirty two U.S. states and more than seventy countries through its insurance subsidiaries. The company operates in two business segments namely the Domestic Insurance and International Insurance segments.. The company majority generates revenues from Life Insurance segment. Company operates in USA, Columbia, Taiwan, Venezuela, Ecuador, Argentina, and Others.
About GLSI Greenwich LifeSciences Inc.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9-amino-acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including breast cancers at low (1+), intermediate (2+), and high (3+ or overexpressing) levels.